BioGroup - Testing the pricing outlook - Model Update - Positioning

We have updated our analysis following BioGroup’s Q3 results, refining our view of performance across the capital structure and identifying several potential trading opportunities. Our assessment leverages the extensive comparative work we previously conducted on Cerba, while recognising the distinct dynamics at play for BioGroup, including its differing leverage profile and the additional strategic options available to the Company. However, the outlook is influenced by the evolving landscape of French tariff expectations. Combining these forces into our analysis, we arrive at our overall investment assessment.

Tomás Mannion